Chen Bin, Liu Lifen, Xu Haiyan, Yang Yijin, Zhang Ling, Zhang Fengchun
Department of Oncology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu 215000, P.R. China.
Department of Gynecology and Obstetrics, Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
Exp Ther Med. 2015 Mar;9(3):1063-1067. doi: 10.3892/etm.2015.2217. Epub 2015 Jan 26.
The aim of this study was to compare the immune function of patients with cervical cancer and the cancer recurrence rate in patients treated with biological immune therapy combined with chemotherapy or with chemotherapy only. A total of 79 postoperative patients with cervical cancer participated in the present study. They were randomly divided into a control group and an experimental group. Patients in the control group were treated with cisplatin chemotherapy. Patients in the experimental group were treated with dendritic cell-cytokine-induced killer (DC-CIK) cells combined with cisplatin chemotherapy. The CD3, CD4, CD8, CD16, CD56 and CD4CD25 cell ratios in peripheral blood, and the expression levels of perforin, granzyme B (GraB) and CD107a of peripheral blood mononuclear cells (PBMCs) in all patients prior to and following treatment were observed. The changes of immune function and recurrence rate between these two groups prior to and following treatment were compared. Prior to treatment, the lymphocyte ratio had no significant difference between the two groups (P>0.05). Following treatment, the lymphocyte ratio in the experimental group was significantly higher than that in the control group (P<0.05). The positive expression levels of perforin, GraB and CD107a of PBMCs in the experimental group following treatment were significantly higher than those prior to treatment and those of the control group (P<0.05). The cumulative recurrence rate in the experimental group was significantly lower than that in the control group (P<0.05). In conclusion, in postoperative patients with cervical cancer, treatment with DC-CIK cells combined with cisplatin chemotherapy significantly improved the immune function, reduced the recurrence rate and prolonged the survival time of the patients.
本研究旨在比较宫颈癌患者的免疫功能以及接受生物免疫治疗联合化疗或单纯化疗的患者的癌症复发率。共有79例宫颈癌术后患者参与了本研究。他们被随机分为对照组和实验组。对照组患者接受顺铂化疗。实验组患者接受树突状细胞因子诱导的杀伤细胞（DC-CIK）联合顺铂化疗。观察了所有患者治疗前后外周血中CD3、CD4、CD8、CD16、CD56和CD4CD25细胞比例，以及外周血单个核细胞（PBMC）中穿孔素、颗粒酶B（GraB）和CD107a的表达水平。比较了两组患者治疗前后免疫功能和复发率的变化。治疗前，两组患者的淋巴细胞比例无显著差异（P>0.05）。治疗后，实验组的淋巴细胞比例显著高于对照组（P<0.05）。实验组治疗后PBMC中穿孔素、GraB和CD107a的阳性表达水平显著高于治疗前及对照组（P<0.05）。实验组的累积复发率显著低于对照组（P<0.05）。总之，在宫颈癌术后患者中，DC-CIK细胞联合顺铂化疗可显著改善患者的免疫功能，降低复发率，延长患者的生存时间。
